Kyverna Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -351 | -368 | -415 | -515 |
EBITDA | -41,016 | -36,992 | -36,365 | -41,552 |
EBIT | -41,367 | -37,360 | -36,780 | -42,067 |
Net Income | -39,728 | -37,804 | -36,787 | -42,081 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -41,597 | -33,522 | -43,713 | -32,153 |
Cash | 32,194 | 124,093 | 34,164 | 53,440 |
Basic Shares | 60,434 | 47,155 | 43,415 | 43,225 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $7,025 |
Gross Profit | -1,799 | -2,133 | -1,707 | 7,025 |
EBITDA | -159,019 | -125,202 | -58,472 | -27,777 |
EBIT | -160,818 | -127,335 | -60,179 | -28,828 |
Net Income | -161,307 | -127,477 | -60,366 | -28,893 |
Net Change In Cash | 0 | 0 | 0 | 7,025 |
Free Cash Flow | -153,717 | -116,455 | -53,031 | -36,881 |
Cash | 124,093 | 96,621 | 34,647 | 37,735 |
Basic Shares | 44,259 | 38,334 | 673,622 | 25,803 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.65 |
2025-12-31 | -$0.80 |
2025-09-30 | -$0.85 |
2025-06-30 | -$0.97 |